Baidu
map

2022年3月11日简报:本土连续新冠病毒感染超500人;德国韩国日增均超30万,均创新高,欧洲多国疫情重新抬头;日本预计今夏开放第四剂新冠疫苗接种

2022-03-11 MedSci整理 MedSci整理

截至北京时间2022年3月11日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿5292万例,新增1,550,689例,达到452,928

截至北京时间2022年3月11日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎COVID-19)病例超过4亿5292万例,新增1,550,689例,达到452,928,405例。累计死亡病例604.9万例,达到6,049,774例。新增死亡为5,994例。康复为387,288,316例,重症和危重症病人达到67,395例;全球新冠确诊病例超过100万例的国家和地区达56个,125个国家和地区病例超10万例。昨日报道:2022年3月10日简报:本土感染连续3天超500例,无头疫情增多;香港新增25991例确诊病例,疫情好转;中国医药确认拿下2022年度辉瑞新冠特效药在大陆的销售权

 

广州新增病例基因测序为奥密克戎BA.1.1

第一是病毒基因测序的结果。昨天外地通报的病例,基因测序由广东省疾控中心测序完成,显示是奥密克戎BA.1.1进化分支;而今天新报告的这一例病例,广州市疾控中心也完成了基因测序,也是奥密克戎BA.1.1进化分支。两者是属于同一个进化分支。

第二是根据流行病学调查结果来看,通过流调问询和现场监控,我们看到在3月6日下午,在销售档口,这两人有近距离聊天,并且有过一些肢体接触,新报告病例没有佩戴口罩。

欧洲多国疫情重新抬头,原因不明,尚待观察

日本东京感染奥密克戎BA.2的病例上升至12.3%

据日本放送协会(NHK)消息,截止到当地时间3月10日23时59分,在过去24小时内,日本报告新增新冠肺炎确诊病例61155例;新增相关死亡病例188例。

截至目前,日本累计确诊病例5619321例,累计死亡25734例。

截至3月9日,东京新增阳性病例的七天平均数为9379例,几乎是2月8日18000例高峰时的一半;但疑似感染奥密克戎亚型突变株BA.2的病例比例上升至12.3%。

在3月10日的东京都政府监测会议上,专家们将日本首都的感染情况和医疗保健供应系统依然维持在最严重的水平。

日本专家指出,虽然目前BA.2的传播速度没有德尔塔或奥密克戎原始毒株快,但需要对其保持警惕。

美国新增超4.4万例确诊病例 美媒:美国超1/4国会议员曾感染新冠病毒

根据Worldometer实时统计数据,截至北京时间2022年3月11日6时30分左右,美国累计确诊新冠肺炎病例81088512例,累计死亡病例990446例。与前一日6时30分数据相比,美国新增确诊病例44617例,新增死亡病例1891例。

美国《国会山报》的分析数据显示,新冠疫情以来,美国已有超过1/4的众议院和参议院议员报告曾感染新冠病毒。自2020年1月以来,美国共有152名来自众议院和参议院的议员感染了新冠病毒。其中,共和党人共计82人,民主党人69人,无党派人士1人。

韩国新增超32万例确诊病例 连续两天超过30万例

据人民网报道,韩国中央防疫对策本部3月10日通报,截至当天0时,韩国较前一天0时新增感染新型冠状病毒确诊病例327549例,累计确诊5539650例。单日新增病例较前一天减少14889例,连续两天超过30万例,为1周前(3月3日)的1.6倍,为2周前(2月24日)1.9倍。据观测,疫情已基本接近顶峰,今后1-2周将出现拐点。

韩国开学仅一周,17万学生感染疫情

韩国教育部在近日表示:“从3月2日新学期开学后的6天时间里,韩国就有174603名学生被确诊为疫情感染者,平均每天都有29100名学生和2490名教职工被确诊。除此以外,有1069028人因为疫情没法上学,这个数字占比韩国所有学生总数的18.1%”。这些数据确实让人有些“叹为观止”,要知道在去年全年,韩国有320232名学生被感染,但新学期开学仅6天,就突破了去年总数的一半。不过,疫情死亡的人大部分都是65岁以上的老年人。

香港新增24390例新冠肺炎确诊病例

香港特区政府卫生署卫生防护中心10日公布,截至当日零时,香港新增24390例经核酸检测确诊的新冠肺炎病例。

3月9日,新冠病毒快速抗原测试阳性结果人士申报系统再接获7012例呈报病例。

据香港医管局介绍,过去24小时,有180名确诊患者在公立医院离世。

德国新增超26万例确诊病例 累计确诊逾1650万例,可能会出现新一波疫情

据央视新闻客户端报道,根据德国联邦疾控机构罗伯特·科赫研究所发布的最新数据,截至当地时间3月10日0时,德国累计确诊新冠肺炎病例16504822例,较前一日新增确诊262752例;累计死亡125023例,较前一日新增259例。全国7天内每10万人发病率为1388.5,已连续8天呈上升态势。

德国联邦政府新冠疫情专家委员会成员卡德拉里当天警告称,德国已经进入第六波疫情。

法国新增超7.4万例确诊病例 疫情出现反弹趋势

据央视新闻客户端报道,当地时间10日,根据法国公共卫生署的统计,法国单日新增新冠确诊病例74818例,疫情出现反弹趋势。自疫情暴发以来,法国累计新冠确诊病例达23308880例。目前法国共有新冠在院治疗患者20287人,其中重症患者1928人。过去24小时,新增新冠死亡病例100例,法国目前累计死亡人数达到140357例。

日本预计今夏开放第四剂新冠疫苗接种

不具名的日本卫生官员表示,日本政府正在考虑最快于今年夏天为民众接种第四剂新冠疫苗。消息称,预计日本政府将获得剂量的辉瑞和莫德纳新冠疫苗。本次接种预计将向接种第三针至少6个月的民众开放。此外,第四剂也将向像以前的疫苗一样免费提供。

国家卫健委:3月9日新增新冠肺炎确诊病例528例 其中本土病例402例

据国家卫生健康委员会官方网站消息,3月9日0—24时,31个省(自治区、直辖市)和新疆生产建设兵团报告新增新冠肺炎确诊病例528例。其中境外输入病例126例(上海42例,广东33例,北京14例,广西12例,河南7例,四川4例,甘肃4例,黑龙江3例,浙江3例,云南2例,江苏1例,福建1例),含17例由无症状感染者转为确诊病例(广东5例,北京4例,浙江3例,四川3例,河南2例);本土病例402例(吉林165例,其中吉林市134例、长春市23例、延边朝鲜族自治州7例、松原市1例;山东66例,其中青岛市56例、威海市7例、淄博市2例、烟台市1例;甘肃66例,其中兰州新区40例、兰州市19例、白银市7例;陕西21例,其中西安市13例、宝鸡市7例、汉中市1例;天津19例,其中西青区14例、津南区2例、北辰区2例、武清区1例;广东17例,其中深圳市15例、阳江市1例、东莞市1例;江苏13例,均在连云港市;河北10例,其中邢台市7例、廊坊市2例、沧州市1例;北京4例,其中朝阳区2例、海淀区2例;辽宁4例,均在沈阳市;上海4例,其中静安区1例、虹口区1例、闵行区1例、浦东新区1例;内蒙古3例,均在呼和浩特市;浙江3例,其中杭州市1例、温州市1例、衢州市1例;云南3例,其中德宏傣族景颇族自治州2例、保山市1例;山西2例,均在运城市;河南2例,均在濮阳市),含10例由无症状感染者转为确诊病例(辽宁3例,山东3例,山西2例,吉林1例,云南1例)。无新增死亡病例。新增疑似病例10例,均为境外输入病例(均在上海)。

当日新增治愈出院病例126例,解除医学观察的密切接触者8550人,重症病例较前一日减少1例。

31个省(自治区、直辖市)和新疆生产建设兵团报告新增无症状感染者586例,其中境外输入151例,本土435例(吉林179例,其中吉林市149例、长春市25例、延边朝鲜族自治州5例;山东112例,其中青岛市91例、威海市14例、淄博市6例、烟台市1例;上海76例,其中闵行区23例、嘉定区16例、浦东新区9例、松江区9例、徐汇区6例、静安区3例、黄浦区2例、杨浦区2例、宝山区2例、长宁区1例、普陀区1例、虹口区1例、奉贤区1例;云南22例,均在德宏傣族景颇族自治州;甘肃11例,其中白银市5例、兰州新区5例、兰州市1例;黑龙江9例,均在牡丹江市;河北5例,其中沧州市2例、廊坊市1例、石家庄市1例、邢台市1例;江苏5例,其中连云港市3例、苏州市1例、扬州市1例;广东5例,均在东莞市;天津2例,其中河东区1例、西青区1例;辽宁2例,均在沈阳市;安徽2例,均在宿州市;河南2例,均在濮阳市;北京1例,在海淀区;广西1例,在防城港市;青海1例,在西宁市);当日转为确诊病例27例(境外输入17例);当日解除医学观察70例(境外输入58例);尚在医学观察的无症状感染者3238例(境外输入1328例)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1258148, encodeId=563f1258148f6, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286073, encodeId=3bd912860e37f, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1294659, encodeId=aeca12946592d, content=<a href='/topic/show?id=ca6e592189b' target=_blank style='color:#2F92EE;'>#日本#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59218, encryptionId=ca6e592189b, topicName=日本)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1334930, encodeId=e35f133493032, content=<a href='/topic/show?id=d16910002215' target=_blank style='color:#2F92EE;'>#韩国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100022, encryptionId=d16910002215, topicName=韩国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=99cf2500102, createdName=zjshifan_98647306, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339445, encodeId=d09e1339445f4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394391, encodeId=b273139439167, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Mar 12 22:41:33 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201647, encodeId=9e9a120164ef6, content=疫情快结束!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dec22608622, createdName=gujie_happy, createdTime=Fri Mar 11 10:03:17 CST 2022, time=2022-03-11, status=1, ipAttribution=)]
    2022-03-11 gujie_happy

    疫情快结束!

    0

相关资讯

2022年3月7日简报:香港昨日新增31008例确诊病例,连续3天下降;本土病例散发,超过10个省份,多为轻症或无症状感染者

截至北京时间2022年3月7日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿4633万例,新增1,149,791例,达到446,335,

日本盐野义口服新冠病毒治疗药物Ensitrelvir(S-217622),治愈率达100%

总部位于大阪府的日本制药公司——盐野义制药公司研发的治疗新冠病毒的口服药,已经于2月25日,向日本厚生劳动省正式递交了临床治疗认可申请。消息显示,这一款日本国产的新冠口服药&l

新冠病毒变异快、易跨种传播,需警惕动物中流行的变异株回传到人类:回眸

新冠疫情暴发以来,由于防控力度不一,部分国家新冠疫情反复,甚至出现一定时期内的失控局面。这一形势加大了全球有效抗击疫情的难度,中国则面临着境外病毒输入的威胁。

上海昨日新增本土确诊3例 本土无症状62例:上海疫情全新消息(2022.3.9)

目前,已追踪到确诊病例在本市的密切接触者19人,均已落实集中隔离观察。

Research Square:高福院士发布华南海鲜市场调查报告:未发现市场动物与新冠关联,该市场非新冠疫情源头

随着德尔塔(Delta)和奥密克戎(Omicron)等新冠变异株的出现,近期国内疫情形势再度紧张了起来,其中香港的疫情十分严峻,3月4日新增52523例确诊病例,新增136例死亡病例。

Baidu
map
Baidu
map
Baidu
map